PATIENT ALERT: If you have tested positive for COVID in the last 14 days, please notify us and reschedule your appointment. Online COVID pre-screening is REQUIRED 72 hours prior to your appointment. Please CLICK HERE to complete the questionnaire.  Masks are still required in all offices.   Information regarding COVID-19.  

Clinical Research & Trials

Available Trials at VOA in Hampton Roads and Eastern North Carolina

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies, and clinical trial resources. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads and Eastern North Carolina. You do not have to leave the area to receive premier cancer care and the latest cancer treatments.

If you are interested in learning more about our cancer research program, you can read frequently asked questions answered by the clinical trial specialists at Virginia Oncology Associates. You can also call our Research Department at a VOA clinical trial location in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach

Breast Cancer Research

  • USO 21455

    A Phase Iii,Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo+Taxane In Patients With Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally-Advanced Or Metastatic Breast Cancer (Wo43571)

    Available at 1 location

    View Details

  • USO 21537

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician¡¯s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

    Available at 4 locations

    View Details

  • USO 21536

    A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (GS-US-592-6173)

    Available at 4 locations

    View Details

  • USO 21234

    A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor (V3002401) ARTEST

    Available at 5 locations

    View Details

  • USO 20210

    Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

    Available at 4 locations

    View Details

  • USO 21173


    Available at 1 location

    View Details

  • uso 21448

    A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)

    Available at 4 locations

    View Details

  • uso 21205

    A Phase II, Multicenter, Randomized, Open-Label, Active-Controlled Study To Assess The Safety And Efficacy Of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) In Combination With Fulvestrant In Participants With HR+, HER2-, Advanced Breast Cancer With A PIK3CA Mutation Following Progression On/After Endocrine-Based Therapy ( EPIK-B4):(CBYL719C2202)

    Available at 4 locations

    View Details

  • uso 20408

    A Phase Ill, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor - Positive, Her2‑Negative Early Breast Cancer (Go42784)

    Available at 5 locations

    View Details

  • USO 20418

    A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY (GSK 213831)

    Available at 4 locations

    View Details

  • USO 21225

    A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens (ACE-Breast-03)

    Available at 3 locations

    View Details

  • USO 20396

    Available Locations Critical Document Checklist SAE List my Site 20396 Patients Training Log Generate Document(Florence) my Site 20396 Training Monitoring Calendar CRF Summary A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) (D967UC00001)

    Available at 5 locations

    View Details

  • USO 20417

    A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

    Available at 4 locations

    View Details

  • D9673C00007 (DESTINY-Breast12)

    “An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer(DESTINY-Breast12)”

    Available at 1 location

    View Details

  • USO 19241

    A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001)

    Available at 4 locations

    View Details

  • USO 19226

    A Phase Iii Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Gdc-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (Bo41843)

    Available at 3 locations

    View Details

  • USO 19122

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Alpelisib (BYL719) In Combination With Nab-Paclitaxel In Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (PIK3CA) Mutation Or Phosphatase And Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (CBYL719H12301)

    Available at 2 locations

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 3 locations

    View Details

GYN Cancer Research

  • USO 21253

    A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

    Available at 2 locations

    View Details

  • uso 21369

    A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) PICCOLO

    Available at 2 locations

    View Details

  • USO 20398

    A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors (Wo42178/Engot-Gyn2/Gog-3051)

    Available at 2 locations

    View Details

Gastrointestinal Cancer Research

  • USO 21235

    A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

    Available at 5 locations

    View Details

  • uso 21326

    A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102 (20210098))

    Available at 1 location

    View Details

  • Alliance A021703

    A021703: Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS).

    Available at 5 locations

    View Details

  • USO 20235

    A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer: PRESERVE 1 (G1T28-207)

    Available at 4 locations

    View Details

Genitourinary Cancer Research

  • USO 21454

    A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

    Available at 5 locations

    View Details

  • uso 20361

    A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer PSMAfore:(CAAA617B12302)

    Available at 3 locations

    View Details

  • uso 21207

    (PSMAddition): An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(CAAA617C12301)

    Available at 2 locations

    View Details

  • USO 20172

    A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

    Available at 1 location

    View Details

  • USO 20248

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

    Available at 1 location

    View Details

  • USO 20403

    A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer D910PC00001:(VOLGA)

    Available at 1 location

    View Details

  • USO 19144

    Biomarker Study To Determine Frequency Of DNA-Repair Defects In Men With Metastatic Prostate Cancer (64091742PCR0002)

    Available at 4 locations

    View Details

  • USO 18283

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

    Available at 2 locations

    View Details

Hematology

  • USO 20219

    A Dual-Cohort, Open-Label, Phase 2 Study Of Brentuximab Vedotin And CHP (A+CHP) In The Frontline Treatment Of Subjects With Peripheral T-Cell Lymphoma (PTCL) With Less Than 10% CD30 Expression (SGN35-032)

    Available at 5 locations

    View Details

Leukemia & Lymphoma Research

  • USO 20133

    A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) MOR208C310:

    Available at 5 locations

    View Details

  • USO 18281

    A Phase 1a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01)

    Available at 1 location

    View Details

Lung Cancer Research

  • USO 21219

    A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies:RMC-4630-03

    Available at 0 locations

    View Details

  • USO 20137

    A Phase III, Open-Label, Randomized Study Of Atezolizumab And Tiragolumab Compared With Durvalumab In Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (GO41854)

    Available at 5 locations

    View Details

Multiple Myeloma

  • USO 19247

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

    Available at 4 locations

    View Details

Solid Tumors Research

  • USO 20283

    A Phase 2 Study Of Brentuximab Vedotin In Combination With Pembrolizumab In Subjects With Metastatic Solid Malignancies After Progression On Prior PD-1 Inhibitor Treatment (SGN35-033)

    Available at 4 locations

    View Details

  • USO 19151

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR

    Available at 1 location

    View Details

  • USO 18057

    A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

    Available at 0 locations

    View Details

Lymphoma & Hematologic

  • uso 21171

    A Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI In Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase (CABL001J12301)

    Available at 1 location

    View Details

  • USO 19070

    Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells (Gc-Ltfu-001).

    Available at 1 location

    View Details

Cellular & Gene

  • uso 21412

    A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)

    Available at 1 location

    View Details

  • uso 21411

    A Phase I, Open-Label, Multicenter Study of FT538 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors (FT538-102)

    Available at 1 location

    View Details